$52.40
Manufacturer: Hungary
Treatment of bronchial asthma.
As adjunctive therapy for bronchial asthma in patients with mild to moderate persistent asthma that is insufficiently controlled by inhaled corticosteroids, and in patients with insufficient clinical control of asthma with short-acting β-adrenoceptor agonists.
Description
Singlon (montelukast) coated tablets 10 mg. №28
Composition
active substance: montelukast;
1 film-coated tablet contains 10 mg of montelukast (in the form of montelukast sodium – 10.4 mg);
Excipients: lactose monohydrate, microcrystalline cellulose, hydroxypropylcellulose, croscarmellose sodium, magnesium stearate, hypromellose, titanium dioxide (E 171), macrogol, iron oxide yellow (E 172).
Dosage form
Film-coated tablets.
Main physical and chemical properties: film-coated tablets, round, biconvex, yellow, embossed “R 15” on one side, with a diameter of approximately 8 mm.
Pharmacotherapeutic group
Means for systemic use in obstructive airways diseases. Leukotriene receptor antagonists.
ATX code R03D C03.
Pharmacological properties
The specified drug belongs to the group of cystenyl-leukotriene receptor blockers, which play an important role in the development of broncho-obstructive syndrome.
As a result, the drug is effective in the treatment of obstructive diseases that develop in the lower parts of the respiratory system.
Montelukast, which is the main active ingredient of the drug, has the property, when applied, to bind to cystenyl-leukotriene receptors (CysLT1 receptors), which are responsible for the occurrence of bronchospasm, sputum secretion from the bronchi, and other symptoms accompanying obstructive bronchitis.
Capable of inhibiting bronchoconstriction in patients with asthma.
It has the property of stopping the arising bronchospasm at all stages of its development, due to the ability to reduce the body’s response to allergic antigens.
The use of montelukast leads to a decrease in the number of eosinophils in the airways.
Indications
Singlon, 10 mg film-coated tablets, is indicated for adults and adolescents 15 years of age and older.
- Treatment of bronchial asthma:
as adjunctive therapy in bronchial asthma in patients with persistent to moderate asthma, which is insufficiently controlled by inhaled corticosteroids, as well as in insufficient clinical control of asthma with short-acting β-adrenoceptor agonists, which are used if necessary. In patients with asthma taking Singlon, this medicine also relieves the symptoms of seasonal allergic rhinitis. - Prevention of asthma, the dominant component of which is exercise-induced bronchospasm.
- Relief of symptoms of seasonal and perennial allergic rhinitis.
The risks of psychoneurological symptoms in patients with allergic rhinitis may outweigh the benefits of using Singlon, so Singlon should be used as a reserve drug in patients with inadequate response or intolerance to alternative therapies.
Contraindications
You should not use the specified drug if the patient has had a previous hypersensitivity (allergy) with respect to one of the components that are part of the drug – both main and auxiliary.
In pediatrics, it is used from 2 years of age.
Application during pregnancy and lactation
Treatment of pregnant women is carried out with every possible care, only for serious indications.
Breastfeeding should be suspended during treatment.
Method of administration and dosage
The dose for patients (aged 15 years) who suffer from bronchial asthma or bronchial asthma with concomitant seasonal allergic rhinitis is 10 mg (1 tablet) 1 time per day, in the evening, regardless of food intake. To alleviate the symptoms of allergic rhinitis, the time of drug use should be selected individually.
General recommendations
The therapeutic effect of the drug Singlon on the control of bronchial asthma lasts 1 day. Patients should be advised to continue taking Singlon even if asthma symptoms are controlled, as well as during periods of exacerbation of bronchial asthma;
Singlon should not be used with other products containing the same active substance – montelukast;
Elderly patients, patients with renal insufficiency or hepatic insufficiency of mild or moderate severity do not require dose adjustment. No data are available in patients with severe hepatic impairment. Doses of the drug for men and women are the same.
Treatment with Singlon, depending on other treatments for bronchial asthma.
Singlon can be added to an existing course of treatment of the patient.
Inhaled corticosteroids: Singlon can be used as an adjunct in the treatment of patients who do not achieve satisfactory clinical control of the disease by the use of inhaled corticosteroids in combination with short-acting
β-agonists used as needed.
Singlon should not abruptly replace inhaled corticosteroids.
Children
- The drug Singlon, film-coated tablets, 10 mg, should be used in children over 15 years of age. The safety and efficacy of Singlon, 10 mg film-coated tablets in children and adolescents under 15 years of age have not been established.
- Chewable tablets, 5 mg to apply to children aged 6 to 14 years.
- Chewable tablets, 4 mg to apply to children aged 2 to 5 years.
Singlon should not be used in children under 2 years of age. Safety and efficacy in children under 2 years of age have not been established.
Overdose
Overdose with this drug does not cause any particular adverse events. In rare cases, the following were observed:
- drowsiness, psychomotor hyperactivity;
- thirst;
- headache;
- vomiting.
Symptomatic therapy is recommended.
Side effects
Usually the drug is well tolerated. Side effects can occur only in rare cases. In particular, there may be observed:
- anaphylactic reactions, hypersensitivity reactions, including anaphylactic shock;
- upper respiratory tract infections;
- headache, abdominal pain, thirst, nausea, vomiting, dyspepsia;
- increased bleeding;
- sleep disturbances, nightmares, hallucinations, insomnia, irritability, anger, agitation, hostility, depression, disorientation, suicidal thoughts;
- lethargy, dizziness, paresthesia, hypersthesia, palpitations;
- hepatitis, increased levels of hepatic transaminases;
- arthralgia, myalgia, including muscle cramps;
- asthenia / fatigue, discomfort, swelling, fever;
- nose bleed.
Recent Reviews